Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
(2022) In Big Data and Society 9(1).- Abstract
- How corporations surveil and influence consumers using big data tools is a major area of research and public debate. However, few studies explore it in relation to physicians in the USA, even though they have been surveilled and targeted by the pharmaceutical industry since at least the 1950s. Indeed, in 2010, concerns about the pharmaceutical industry’s undue influence led to the passing of the Physician Sunshine Act, a unique piece of transparency legislation that requires companies to report their financial ties to physicians and teaching hospitals in a public database. This article argues that while the Sunshine Act has clearly helped expose important commercial influences on both prescribing and the scale of industry involvement with... (More)
- How corporations surveil and influence consumers using big data tools is a major area of research and public debate. However, few studies explore it in relation to physicians in the USA, even though they have been surveilled and targeted by the pharmaceutical industry since at least the 1950s. Indeed, in 2010, concerns about the pharmaceutical industry’s undue influence led to the passing of the Physician Sunshine Act, a unique piece of transparency legislation that requires companies to report their financial ties to physicians and teaching hospitals in a public database. This article argues that while the Sunshine Act has clearly helped expose important commercial influences on both prescribing and the scale of industry involvement with physicians, it has also, paradoxically, fueled further commercial surveillance and marketing. The article casts new light on innovative pharmaceutical marketing approaches and the key role of data brokers and analytics companies in identification, targeting, managing, and surveillance of physicians. We place this analysis within the political economies of the pharmaceutical industry, surveillance-based marketing and transparency, and argue that policies to promote increased transparency must be tightly tied to policies that impede the commodification and use of transparency data for surveillance and marketing purposes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5e30bb4a-c74a-478d-a602-e506cb38f478
- author
- Mulinari, Shai LU and Ozieranski, Piotr
- organization
- publishing date
- 2022-02-09
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Big Data and Society
- volume
- 9
- issue
- 1
- publisher
- SAGE Publications
- external identifiers
-
- scopus:85124721610
- ISSN
- 2053-9517
- DOI
- 10.1177/20539517211069631
- project
- Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations
- language
- English
- LU publication?
- yes
- id
- 5e30bb4a-c74a-478d-a602-e506cb38f478
- date added to LUP
- 2021-12-07 22:30:18
- date last changed
- 2022-04-22 02:23:50
@article{5e30bb4a-c74a-478d-a602-e506cb38f478,
abstract = {{How corporations surveil and influence consumers using big data tools is a major area of research and public debate. However, few studies explore it in relation to physicians in the USA, even though they have been surveilled and targeted by the pharmaceutical industry since at least the 1950s. Indeed, in 2010, concerns about the pharmaceutical industry’s undue influence led to the passing of the Physician Sunshine Act, a unique piece of transparency legislation that requires companies to report their financial ties to physicians and teaching hospitals in a public database. This article argues that while the Sunshine Act has clearly helped expose important commercial influences on both prescribing and the scale of industry involvement with physicians, it has also, paradoxically, fueled further commercial surveillance and marketing. The article casts new light on innovative pharmaceutical marketing approaches and the key role of data brokers and analytics companies in identification, targeting, managing, and surveillance of physicians. We place this analysis within the political economies of the pharmaceutical industry, surveillance-based marketing and transparency, and argue that policies to promote increased transparency must be tightly tied to policies that impede the commodification and use of transparency data for surveillance and marketing purposes.}},
author = {{Mulinari, Shai and Ozieranski, Piotr}},
issn = {{2053-9517}},
language = {{eng}},
month = {{02}},
number = {{1}},
publisher = {{SAGE Publications}},
series = {{Big Data and Society}},
title = {{Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act}},
url = {{http://dx.doi.org/10.1177/20539517211069631}},
doi = {{10.1177/20539517211069631}},
volume = {{9}},
year = {{2022}},
}